InvestorsHub Logo
Followers 0
Posts 267
Boards Moderated 0
Alias Born 03/16/2007

Re: None

Friday, 01/18/2008 4:16:07 AM

Friday, January 18, 2008 4:16:07 AM

Post# of 11073
Quiet board lately. We should be active soon enough with an accurate valuation. I suggest re-reading some of the past PR's if you are bored with the recent lack of price movement. You will be re-assured of your investment. I was reading over the 09-12-07 PR about International sales expanion. With so many affected with diabetes. (230 million worldwide) it will be quite possible and very lucrative to gain a small portion of the market share due to the lack of legitimate competition.

Twenty million, eight hundred thousand children and adults, or 7% of the U.S. population suffer from diabetes. Thirty percent of those diagnosed with diabetes will eventually suffer from peripheral neuropathy, pain and numbness in the feet and hands that can lead to complete loss of mobility, gangrene, and eventual amputations. $132 Billion per year is the current cost of treating diabetes, or 1 of every 10 health care dollars spent. Neuropathy sufferers constitute 33% of this market, or 43.56 billion dollars in potential market. ReBuilder Medical Technologies, Inc. is a company in its infancy that has targeted 1% of this market, or $43.5 million dollars in its next two market years, and is on course to meet this goal. Its only primary competition is from drug companies whose therapy has proven less successful and prone to side-effects and addiction.

That is just the U.S. figures and also doesn't account for the various other products that Reuilder has exclusive rights to. (Molloscum, upcoming products) What else do you need in a company, so far the CEO has lived up to promises.